Brief: Lyra Therapeutics Announces First Patient Treated In Phase 2 Beacon Clinical Trial Of Lyr-220 In Post-Surgical Chronic Rhinosinusitis Patients

Lyra Therapeutics

25/04/2022 12:24

April 25 (Reuters) - Lyra Therapeutics Inc  LYRA.O :
    * LYRA THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED IN PHASE
2
BEACON CLINICAL TRIAL OF LYR-220 IN POST-SURGICAL CHRONIC
RHINOSINUSITIS PATIENTS

Source text for Eikon:  ID:nPn3ZFNxxa 
Further company coverage:  LYRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))